SCHEMBL14735532

SCHEMBL14735532

CN1CCN(Cc2c(O)ccc3c2OCC3=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.54
▸ KMT2A Q03164 7/20 0.54
▸ MEN1 O00255 6/20 0.54
▸ NPSR1 Q6W5P4 5/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ KLK7 P49862 1/20 0.54
▸ MAPT P10636 5/20 0.52
▸ USP2 O75604 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ ERAP1 Q9NZ08 4/20 0.51
▸ GAA P10253 3/20 0.51
▸ PSMB5 P28074 1/20 0.50
▸ ATM Q13315 1/20 0.49
▸ ALDH1A1 P00352 6/20 0.48
▸ RXFP1 Q9HBX9 2/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ PIM1 P11309 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ LMNA P02545 2/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14883923 0.86 PSMB5 (0.53) KDM4EKMT2AMEN1MAPTUSP2
SCHEMBL14883890 0.86 PSMB5 (0.53) KDM4EKMT2AMEN1MAPTUSP2
SCHEMBL14735513 0.85 PSMB5 (0.51) KDM4EKMT2AKLK7MAPTNPC1
SCHEMBL14735316 0.85 PSMB5 (0.46) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14735352 0.85 PSMB5 (0.48) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14735212 0.84 PSMB5 (0.50) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14735205 0.81 VEGFA (0.43) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14735160 0.79 PSMB5 (0.47) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14735157 0.79 PSMB5 (0.47) KDM4EKMT2AMEN1NPSR1SMN1; SMN2
SCHEMBL14734983 0.78 PSMB5 (0.46) KDM4EKMT2AMEN1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 — — EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 — — US disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 — — US disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 — — US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 — — EP disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 — — US disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 — — US disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 — — US disclosed
EP-2565192-A1 ANTICANCER AGENT The University of Tokyo (JP) 2013-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 KDM4E 540/4885KMT2A 576/4885MEN1 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback